L Duck
Overview
Explore the profile of L Duck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baczewska N, Philippart M, Siplet J, Baurain J, Stainier L, Laterre E, et al.
Acta Gastroenterol Belg
. 2023 Jul;
86(2):371-373.
PMID: 37428174
Immunotherapy is becoming more and more relevant in the treatment of advanced melanoma. Proper management of its side effects can prevent severe complications. We describe the case of a 73-year-old...
2.
Lambert E, Hollebosch S, Van Praet C, Van Bruwaene S, Duck L, De Roock W, et al.
Acta Clin Belg
. 2021 Nov;
77(6):897-905.
PMID: 34789066
Introduction: Abiraterone acetate + prednisone (AAP) and docetaxel have proven their efficacy in the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) in clinical trials. However, real-world...
3.
Machiels J, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L
Ann Oncol
. 2020 Jun;
19(3):598-599.
PMID: 32560013
No abstract available.
4.
Vanhaudenarde V, Duck L, Mazzeo F, Graux C, Jamar F, Coche E, et al.
Acta Clin Belg
. 2013 Aug;
68(2):120-3.
PMID: 23967721
Haemangiopericytoma is a rare tumor of vascular origin. We report the case of patient with severe refractory anaemia due to peripheral destruction of red blood cells by spleen metastases. Anaemia...
5.
Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, et al.
Support Care Cancer
. 2013 Aug;
21(12):3483-90.
PMID: 23955094
Purpose: To study the treatment patterns, effectiveness and safety of zoledronic acid (ZOL) beyond 2 years of therapy, given the paucity of data on long-term treatment in daily clinical practice....
6.
Janus N, Launay-Vacher V, Byloos E, Machiels J, Duck L, Kerger J, et al.
Br J Cancer
. 2010 Nov;
103(12):1815-21.
PMID: 21063408
Background: half of anticancer drugs are predominantly excreted in urine. Dosage adjustment in renal insufficiency (RI) is, therefore, a crucial issue. Moreover, patients with abnormal renal function are at high...
7.
Machiels J, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L
Ann Oncol
. 2008 Feb;
19(3):597-9.
PMID: 18272908
No abstract available.
8.
Bambust I, Van Aelst F, Joosens E, Schallier D, Kalantari H, Paulus R, et al.
Acta Clin Belg
. 2007 Sep;
62(4):223-9.
PMID: 17849693
In an effort to map the use of interleukin-2 (IL-2) treatment in patients with clear cell renal cell cancer (RCC) in Belgian hospitals, 44 cases were registered from 9 hospitals...
9.
Huygh G, Clement P, Dumez H, Schoffski P, Wildiers H, Selleslach J, et al.
Sarcoma
. 2007 May;
2006:56282.
PMID: 17496996
Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as...
10.
Machiels J, Sempoux C, Scalliet P, Coche J, Humblet Y, Van Cutsem E, et al.
Ann Oncol
. 2007 Jan;
18(4):738-44.
PMID: 17208931
Background: To assess the safety and preliminary efficacy of concurrent radiotherapy, capecitabine, and cetuximab in the preoperative treatment of patients with rectal cancer. Patients And Methods: Forty patients with rectal...